Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

Vertex Pharmaceuticals logo
$392.14 +0.10 (+0.02%)
As of 12:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare

Vertex Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy
Based on 27 Analyst Ratings
Sell
0
Hold
13
Buy
14

Based on 27 Wall Street analysts who have issued ratings for Vertex Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 27 analysts, 13 have given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for VRTX.

Consensus Price Target

$497.10
26.76% Upside
According to the 27 analysts' twelve-month price targets for Vertex Pharmaceuticals, the average price target is $497.10. The highest price target for VRTX is $575.00, while the lowest price target for VRTX is $405.00. The average price target represents a forecasted upside of 26.76% from the current price of $392.15.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for VRTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Vertex Pharmaceuticals and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VRTX Analyst Ratings Over Time

TypeCurrent Forecast
8/29/24 to 8/29/25		1 Month Ago
7/30/24 to 7/30/25		3 Months Ago
5/31/24 to 5/31/25		1 Year Ago
8/30/23 to 8/29/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
12 Buy rating(s)
15 Buy rating(s)
16 Buy rating(s)
Hold
13 Hold rating(s)
14 Hold rating(s)
14 Hold rating(s)
7 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$497.10$512.30$515.04$485.91
Forecasted Upside26.76% Upside9.20% Upside16.26% Upside-1.51% Downside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

VRTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VRTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Vertex Pharmaceuticals Stock vs. The Competition

TypeVertex PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.56
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside26.80% Upside15,704.61% Upside10.24% Upside
News Sentiment Rating
Positive News

See Recent VRTX News
Positive News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/6/2025Canaccord Genuity Group
2 of 5 stars		Whitney Ijem
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetHold ➝ Hold$424.00 ➝ $411.00+6.45%
8/6/2025Guggenheim
2 of 5 stars		Debjit Chattopadhyay
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetBuy ➝ Buy$558.00 ➝ $546.00+40.91%
8/6/2025Wells Fargo & Company
3 of 5 stars		Mohit Bansal
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeEqual Weight ➝ Overweight$460.00+22.67%
8/5/2025Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Greg Harrison
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetSector Perform ➝ Sector Perform$442.00 ➝ $438.00+11.47%
8/5/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Joon Lee
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Set TargetBuy ➝ Buy$520.00 ➝ $490.00+24.70%
8/5/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Brian Abrahams
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetSector Perform ➝ Sector Perform$430.00 ➝ $405.00+3.86%
8/5/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Colin Bristow
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Set TargetBuy ➝ Buy$582.00 ➝ $553.00+37.88%
8/5/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Evan Seigerman
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Set TargetOutperform ➝ Outperform$557.00 ➝ $530.00+12.22%
8/5/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Carter Gould
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetOverweight ➝ Overweight$535.00 ➝ $485.00+2.70%
8/5/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Paul Matteis
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetHold ➝ Hold$494.00 ➝ $455.00-3.66%
8/5/2025HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Andrew S.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetBuy ➝ Buy$550.00 ➝ $478.00+1.21%
8/5/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Matthew Harrison
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Set TargetEqual Weight ➝ Equal Weight$460.00 ➝ $439.00-7.04%
7/14/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Jessica Fye
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetOverweight ➝ Overweight$515.00 ➝ $517.00+9.43%
5/23/2025Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating		H. Engel
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeStrong-Buy ➝ Hold
5/7/2025Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		A. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOutperform ➝ Peer Perform
5/6/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy
5/6/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating		D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeStrong-Buy ➝ Hold
5/6/2025William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform
5/6/2025Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating		David Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingOutperform ➝ Market Perform$550.00 ➝ $503.00+0.56%
5/6/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Joseph Stringer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingHold ➝ Hold
3/31/2025Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Ying Huang
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetBuy ➝ Buy$555.00 ➝ $567.00+15.08%
2/11/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Gena Wang
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetEqual Weight ➝ Equal Weight$435.00 ➝ $467.00+1.35%
1/27/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Christopher Raymond
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetOverweight ➝ Overweight$535.00 ➝ $533.00+20.72%
12/19/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Market Perform
12/9/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Buy$500.00 ➝ $550.00+19.02%
11/14/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$575.00+16.25%
10/10/2024Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		D. Brill
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingMarket Perform
7/23/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$450.00 ➝ $500.00+1.60%
6/27/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating		S. Chesney
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageBuy$545.00+14.98%
6/17/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$465.00 ➝ $550.00+15.48%
4/11/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeIn-Line ➝ Outperform$438.00+10.17%
2/2/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Market Perform
1/31/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeNeutral ➝ Underperform$325.00-25.27%
1/31/2024Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 12:43 PM ET.


Should I Buy Vertex Pharmaceuticals Stock? VRTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, August 26, 2025. Please send any questions or comments about these Vertex Pharmaceuticals pros and cons to contact@marketbeat.com.

Vertex Pharmaceuticals
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Vertex Pharmaceuticals Incorporated:

  • The company recently reported strong earnings, with earnings per share (EPS) of $4.52, surpassing analyst expectations, indicating robust financial health and effective management.
  • Vertex Pharmaceuticals Incorporated achieved a significant revenue increase of 11.3% year-over-year, reflecting its growing market presence and successful product offerings.
  • The current stock price is around $389.68, which may present a favorable entry point for investors looking to capitalize on potential future growth.
  • With a return on equity of 23.91%, the company demonstrates efficient use of shareholder equity to generate profits, which is a positive indicator for investors.
  • Analysts have a consensus target price of $497.10, suggesting potential upside for investors based on current valuations and future growth prospects.

Vertex Pharmaceuticals
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Vertex Pharmaceuticals Incorporated for these reasons:

  • Insider ownership is relatively low at 0.20%, which may indicate a lack of confidence from those closest to the company.
  • Several analysts have downgraded their price targets for the stock, which could signal concerns about future performance and market conditions.
  • The company has faced challenges in the past, including a significant loss in EPS during the same quarter last year, which raises questions about its long-term stability.
  • Market sentiment may be affected by broader economic conditions, which could impact the pharmaceutical sector and Vertex Pharmaceuticals Incorporated's stock performance.
  • With a mix of hold and buy ratings from analysts, there may be uncertainty in the market regarding the stock's future trajectory, leading to potential volatility.

VRTX Forecast - Frequently Asked Questions

According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Vertex Pharmaceuticals is $497.10, with a high forecast of $575.00 and a low forecast of $405.00.

27 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 13 hold ratings, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VRTX shares.

According to analysts, Vertex Pharmaceuticals's stock has a predicted upside of 26.76% based on their 12-month stock forecasts.

Over the previous 90 days, Vertex Pharmaceuticals's stock had 1 upgrade by analysts.

Analysts like Vertex Pharmaceuticals less than other "medical" companies. The consensus rating score for Vertex Pharmaceuticals is 2.56 while the average consensus rating score for "medical" companies is 2.78. Learn more on how VRTX compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NASDAQ:VRTX) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...
Brownstone Research | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...
Goldco Precious Metals | Sponsoredtc pixel
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...
Paradigm Press | Sponsoredtc pixel
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsoredtc pixel
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...
The Oxford Club | Sponsoredtc pixel
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsoredtc pixel
Out of 18,347 Cryptocurrencies... This is the ONLY One
The Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...
Crypto 101 Media | Sponsoredtc pixel